Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

A Type 2 diabetes diagnosis increases the risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, by 55% within 10 years, according to analysis of data from more than 1.6 million patients across the US.

Within the first five years of a Type 2 diabetes diagnosis, the study found that the combined risk of developing CKD or heart failure, or dying, was 33% on average. By year 10, that combined risk rises to 55%.

Key Findings

The study shows within five years of a first diabetes diagnosis, the risk of developing CKD first was more than twice that of developing heart failure first (19.0% vs. 8.3%).

However, among people who developed heart failure first, there was a 42% risk of developing CKD within the following five years.

Conversely, among those who developed CKD first, there was a 23% risk of developing heart failure within the following five years.

"Our findings clearly show how the serious complications associated with type 2 diabetes rise sharply over time as the common combination of obesity, abnormal blood fats, high blood pressure and higher blood sugar damages blood vessels and vital organs," said Professor Naveed Sattar of the University of Glasgow in Scotland, UK.

Why The Findings Matter

Type 2 diabetes is projected to become the world's most prevalent epidemic disease, affecting an estimated 1.3 billion people by 2050.

It frequently occurs alongside obesity, high blood pressure, heart failure, CKD and depression, contributing substantially to the global burden of multi-morbidity.

The researchers say the findings highlight the importance of early, proactive and holistic management of Type 2 diabetes to help reduce the risk of serious complications.

"Our results emphasize the critical importance of detecting and treating type 2 diabetes thoroughly at the earliest opportunity to help reduce the risk of serious complications," Sattar added.

How Was The Study Conducted?

The team included 1,617,508 patients newly diagnosed with diabetes between January 1, 2010, and March 31, 2024, from across the US.

The average age of participants at enrollment was 59, and 51% were female. Among the 13% of patients who had a body mass index (BMI) recorded, the median was 30.9 kg/m².

Almost three-quarters (72%) of participants were living with dyslipidemia, or high levels of cholesterol and other fats in the blood, while more than two-thirds (68%) had high blood pressure.

How Are Diabetes, Kidney Disease And Heart Failure Linked?

The US Centers for Disease Control and Prevention (CDC) explains that diabetes, CKD and heart disease are interconnected.

High blood sugar can gradually damage the kidneys, reducing their ability to filter blood and potentially leading to CKD. When kidney function declines, it can also put additional stress on the heart.

Common Risk Factors

Risk factors that can overlap across diabetes, CKD and heart disease include:

• High blood sugar
• High blood pressure
• Family history
• Obesity
• Unhealthy diet
• Physical inactivity

Tips To Prevent

The CDC recommends lifestyle measures that can help reduce the risk of these conditions and their complications:

• Get active
• Choose healthy foods and drinks
• Quit smoking

A widely used supplement for joint health has been linked to a faster Alzheimer's progression, raising questions about whether glucosamine could turn mild cognitive impairment into dementia.

The study, published in Nature Metabolism, combined an analysis of health records of experiments involving human brain tissue and genetically modified mice. It showed that the supplement affected the brain in people already showing early signs of cognitive decline.

The findings, however, do not prove that glucosamine increases the progression of Alzheimer’s disease faster in humans.

What Is Glucosamine?

Glucosamine is a sugar-related compound widely sold as an over-the-counter supplement for joint discomfort and joint health. It is also found naturally in cartilage. It is used by older adults, the same age group in which cognitive impairment and dementia become more common.

Researchers at the University of Florida analysed health records collected between 2012 and 2024 to investigate whether glucosamine use was linked with Alzheimer's disease and related dementias.

"In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., Director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."

Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds

What Were The Study's Findings?

About 8% of patients in both groups were using glucosamine supplement. This included 2,750 people with mild cognitive impairment and 1,896 people who already had Alzheimer's disease or a related dementia.

After accounting for age, sex and demographic factors, researchers found that people with mild cognitive impairment who used glucosamine had a 25% higher likelihood of progressing to dementia compared with those without documented use.

Among people who already had Alzheimer's disease or a related dementia, glucosamine use was also associated with a 25% higher risk of death during the study period. However, these were findings were based on collective health records, not a controlled clinical trial.

“The electronic health record data are very provocative,” said Matt Gentry, Ph.D., a study co-author. “While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.”

Also read: Rabies Day Exclusive: ‘We Need To Target The Source’ For A Rabies-Free India By 2030, Says Veterinary Epidemiologist

Glucosamine's Effects On Brain

The researchers identified a possible biological explanation involving a process called glycosylation. In simple terms, glycosylation involves attaching sugar structures to proteins. This is a normal process that helps proteins fold correctly, move around cells and perform their functions.

But the researchers found evidence that this process becomes excessively active in Alzheimer's disease. Their analysis suggested that glucosamine may intensify this abnormal “sugar-tagging” process in the brain.

The researchers tested the idea in genetically modified mice. Glucosamine increased the attachment of sugar molecules to proteins inside brain cells. The subjected mice's ability to recognise familiar animals also worsened.

When researchers used a chemical treatment to suppress the sugar-attachment process, the mice showed improved memory performance.

This does not prove the same mechanism occurs in humans, but it gave researchers a possible biological explanation for the association seen in the health records.

The researchers also examined brain tissue from people who had Alzheimer's disease. They found significantly more sugar attachment to proteins in Alzheimer's brain tissue compared to tissue from people without the disease. Taken together, the health-record analysis, mouse experiments and human brain-tissue findings point toward a connection between altered metabolism and Alzheimer's progression.

Despite the observation, a controlled clinical trial is needed to determine whether glucosamine itself accelerates Alzheimer's progression and whether certain patients are vulnerable.

Fighting cancer is “brutal and unrelenting,” said White House Chief of Staff Susie Wiles, who is now cancer-free after undergoing treatment for early-stage breast cancer.

In an op-ed published Sunday in USA Today, Wiles described undergoing chemotherapy while continuing to lead the White House staff for President Donald Trump.

She said some days, simply getting out of bed and going to work took all her strength. The disease, treatment, test results and uncertainty about what came next occupied her thoughts from the moment she woke up and sometimes even while she slept.

‘Even The Strongest Mind Can Be Overtaken’

“Even the strongest mind can be overtaken by it. At times, mine was,” Wiles wrote.

“Fighting for your health while remaining fully committed to your work can feel impossible,” she said, adding that determination and “perhaps some measure of mind over matter” helped her maintain that balance.

Wiles acknowledged that continuing to work during cancer treatment may not be possible or right for everyone. For her, she said, work provided “a mission larger than myself.”

“Maintaining that balance was not easy,” Wiles wrote, saying the experience gave her “profound respect and empathy” for everyone undergoing cancer treatment.

“It drains you physically, mentally, emotionally and spiritually,” she added.

Also read: From 365 Shots To 52: How Could Lilly’s Newly-Approved Weekly Insulin Injection Change Diabetes Care

Wiles said cancer can shrink a person’s world to chemotherapy appointments, blood tests, scans, medications and side effects.

“There is a temptation to measure each day by how sick you feel,” she wrote. She said she worked hard not to let breast cancer become the center of everything.

“I directed as much of my energy as I could toward doing my job,” Wiles wrote. “People depended on me to be strong and clear-eyed, and I was determined not to let them down.”

Her Team Helped Carry The Burden

Wiles said cancer affected her stamina, mobility and focus, making the support of her colleagues crucial.

“People stepped forward without hesitation, filled every gap, carried additional weight and never allowed me to feel that I was carrying this burden alone. I will never be able to repay them,” she wrote.

She also credited her family and two daughters, who “traveled every step of this road with me.”

After surgery, pathology showed no residual cancer. Wiles announced on September 16 that she was cancer-free after receiving clear pathology results at the Mayo Clinic. She had disclosed her early-stage breast cancer diagnosis in March.

She said chemotherapy tested her in ways she could never have anticipated. Her next stage, she added, will involve rebuilding what treatment took from her.

“Cancer does not have to take away who you are,” she wrote.

Wiles Thanks Trump And Her Family

Wiles thanked Trump “for the kindness and compassion” he showed while she was undergoing treatment.

Trump had publicly praised Wiles during her cancer battle, saying in a prerecorded message in May that she was winning her fight.

Wiles also credited her family, friends, colleagues and doctors for helping her through the ordeal.

In a post on X, she said she rarely writes about herself but wanted to share what it was like to fight cancer while continuing to do a job she loves.

“Cancer tried to make my world smaller. I was determined not to let it,” she wrote. She said she hoped her account could offer strength to someone still fighting the disease.